Reconstitute full-length C1q to be truly "full"-functional

Author: Senior Product Manager of UA Views：19

Complement component C1q is a key molecule in the human immune system. As the initiator of the classical complement activation pathway, it can recognize pathogens, immune complexes, and altered self-components, and trigger downstream immune cascades by activating its associated proteases C1r and C1s. However, C1q itself is an extremely complex protein—it is assembled from 18 polypeptide chains. This complexity has long hindered in-depth research into its functional mechanisms, while the purification of native C1q from serum poses limitations in terms of reproducibility and biosafety. The breakthrough in recombinant full-length C1q protein technology has provided scientists with a powerful tool, greatly advancing research in complement biology and related diseases.

Recent Advances
Product Information

Recent Advances

Full-Length Recombinant C1q: The Key to "Full" Functionality

Complement component C1q is a critical molecule in the human immune system. As the initiating molecule of the classical complement activation pathway, it recognizes pathogens, immune complexes, and altered self-components, triggering downstream immune cascades by activating its associated proteases C1r and C1s. However, C1q itself is an extraordinarily complex protein—composed of 18 polypeptide chains. This complexity has long hindered in-depth studies of its functional mechanisms, while purification of natural C1q from serum faces limitations in reproducibility and biosafety. The breakthrough in full-length recombinant C1q protein technology provides scientists with a powerful tool, significantly advancing research in complement biology and related diseases.

1. The Complex Structure of C1q: A "Bouquet"-Shaped Molecular Machine

Source: Frontiers in Immunology

To appreciate the value of full-length recombinant C1q, one must first understand the intricate structure of C1q itself. C1q is a hexameric molecule composed of three different types of polypeptide chains (A, B, and C chains). Specifically, it consists of 6 A chains, 6 B chains, and 6 C chains—totaling 18 polypeptide chains. Each chain contains an N-terminal collagen-like region and a C-terminal globular C1q domain.

These 18 chains further assemble into 6 heterotrimeric subunits (A-B-C), each featuring a "stem" formed by the collagen-like regions and a "head" formed by the globular domains. Ultimately, the entire C1q molecule adopts its iconic "bouquet" structure—six bundles of collagen-like helices radiating outward from a central point, each terminating in a trimeric globular head.

This elaborate multimeric structure endows C1q with remarkable functionality: its globular heads are responsible for recognizing and binding various ligands, including immunoglobulins (IgG and IgM) and pentraxins, while the collagen-like tails mediate immune effector functions such as binding to the C1r/C1s proteases.

2. Expression of Full-Length Recombinant C1q: Overcoming Technical Challenges

Precisely because of its structural complexity, recombinant expression of C1q has been a formidable challenge. Early methods relied primarily on purification from human serum, but this approach suffers from low yields, batch-to-batch variability, and potential pathogen contamination risks.

UA BIOSCIENCE has successfully expressed recombinant human C1q with a C-terminal FLAG tag, demonstrating biochemical and structural properties highly similar to serum-derived natural C1q.

C1q Flag Tag Full Length Protein, Human(UA016164)

Immobilized Anti-CD20 Monoclonal Antibody (Rituximab) at 10 μg/mL (100 μL/well) can bind C1q Flag Tag Protein, Human with EC50 of 0.60-0.74 μg/ml.

These results indicate that full-length recombinant C1q is a reliable and effective substitute for studying the functions of natural C1q.

3. Applications of Full-Length Recombinant C1q: From Basic Research to Clinical Potential

The advent of full-length recombinant C1q technology has opened new doors in complement biology research, with broad application prospects.

1. Detailed Analysis of Structure-Function Relationships
This is the most direct and powerful application of recombinant C1q. Using site-directed mutagenesis, researchers can introduce amino acid substitutions at specific positions in recombinant C1q and observe the functional consequences, thereby precisely identifying critical functional sites.

For example, using rC1q mutants, researchers have pinpointed key residues involved in C1q's interaction with the C1r/C1s proteases. Studies reveal that LysB61 and LysC58 in the collagen-like region play central roles in this interaction, likely forming salt bridges with acidic Ca²⁺ ligands on the CUB domains of C1r/C1s to mediate binding.

2. Engineering and Novel Molecule Design
The full-length recombinant C1q platform also enables the creation of C1q variants with tailored functionalities. Researchers have successfully designed and produced single-chain forms of the C1q globular head (ghC1q). Through rational design and yeast surface display screening, ghC1q variants with enhanced IgM-binding capacity have been obtained. These engineered variants effectively inhibit complement activation in competition assays, highlighting the potential of engineered C1q as potent inhibitors or activators of the classical complement pathway.

3. Advancing Disease Models and Therapeutic Research
Recombinant C1q technology is also extending into disease research and therapy. For instance, researchers have successfully developed humanized C1Q mouse models (B-hC1Q mice) by replacing the mouse C1qa, C1qb, and C1qc genes with their human counterparts, providing a more human-relevant model for preclinical studies of antibody-mediated complement-dependent cytotoxicity (CDC) therapies.

Moreover, the C1q and its receptor (e.g., gC1qR) axis are emerging as novel immune checkpoint inhibitor targets in cancer therapy. Simultaneously, targeting C1q signaling pathways shows promise in preventing regenerative fibrosis in aged muscles. Full-length recombinant C1q will be a key tool in developing drugs targeting these pathways and validating their mechanisms of action.

Conclusion

The successful expression of full-length recombinant C1q represents a significant technological leap in complement research. Overcoming the limitations of natural C1q—its scarcity and structural complexity—this achievement provides scientists with an "on-demand" powerful tool. It not only enables molecular-level insights into the workings of this intricate immune molecule but also paves the way for developing novel immunomodulatory therapies for a range of diseases, from cancer to fibrosis. As the technology continues to advance, research based on full-length recombinant C1q will undoubtedly uncover new secrets of this ancient molecule and spur further innovative clinical applications.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next